ICML 2019 | Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL

Sasanka Handunnetti

Sasanka Handunnetti, MBBS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the use of an undetectable peripheral blood MRD status as a therapeutic goal in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated with venetoclax in a retrospective analysis. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video